Freedom of Information

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.
Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
   • Azacitidine monotherapy
   • Low dose cytarabine (LoDAC) monotherapy
   • Venetoclax + azacitidine
   • Venetoclax + LoDAC
   • Ivosidenib
   • Intensive chemotherapy-based regimen
   • Other
2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
   • Azacitidine monotherapy
   • Low dose cytarabine (LoDAC) monotherapy
   • Venetoclax + azacitidine
   • Venetoclax + LoDAC
   • Ivosidenib
   • Intensive chemotherapy-based regimen
   • Other
   Note: this should only include patients who have started first-line treatment during the 6-month window
3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

Patients with chronic lymphocytic leukaemia (CLL)
4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?
Note: this should include patients who started treatment prior to the 6-month window
5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?